Alzheimer's Drug Discovery Foundation - Drug Discovery RFP 2018

The Alzheimer's Drug Discovery Foundation (ADDF) invites applications for the Drug Discovery RFP. Upcoming deadline for the submission of a Letter of Intent is April 13, 2018. The average award is between $ 150,000 - $ 600,000 based on stage and scope of research. The duration is one year with potential for follow-on funding. Multi-year proposals can be considered.

Funding is open to researchers, clinicians, and postdoctoral fellows working in academic medical centers and universities or nonprofits, or in biotechnology companies that demonstrate a clear need for nonprofit funding.

ADDF has long recognized the need to bridge the translational funding gap between early-stage drug discovery and clinical development for Alzheimer's disease, related dementias, and cognitive aging by supporting promising therapeutic approaches. The ADDF's Drug Discovery programme RFP focuses on supporting programs that aim to:

• Advance novel lead molecules to the clinical candidate selection stage (defined as compounds suitable for IND-enabling studies); or
• Build preclinical evidence in relevant animal models for repurposed/repositioned drugs.

The RFP aims to support in vivo pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies for novel therapeutics, including small molecules and biologics (e.g., antibodies, oligonucleotides, peptides, gene therapy), and for repurposed/repositioned drugs or natural products.